Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. O'Donnell (Washington, DC, United States of America), J. Froehlich (Hayward, CA, United States of America), B. Thompson (Owings Mills, MD, United States of America), J. Dahms (Hayward, CA, United States of America), D. Cipolla (Hayward, CA, United States of America), A. Davis (Research Triangle Park, NC, United States of America), I. Gonda (Hayward, CA, United States of America), C. Haworth (Cambridge, United Kingdom). Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections. 2682

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA) Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Source: Eur Respir J 2013; 41: 1107-1115 Year: 2013 Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study Source: Eur Respir J 2009; 34: 1072-1078 Year: 2009 A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Lung function, symptoms and inflammatory biomarkers in patients with bronchiectasis (brx) with and without chronic pseudomonas aeruginosa (psa) colonisation Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Early re-colonization with pseudomonas aeruginosa (PA) after treatment: a possible risk factor for development of chronic infection in cystic fibrosis (CF) patients Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008 Severe exacerbations of chronic obstructive pulmonary disease (COPD) due to Pseudomonas aeruginosa: resistance to common antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 540s Year: 2001 Pseudomonas aeruginosa infections Source: Respipedia Article Year: 2018 Serial measures of airway function in infants & preschoolers with cystic fibrosis (CF) according to pseudomonas aeruginosa (PsA) status Source: Eur Respir J 2007; 30: Suppl. 51, 449s Year: 2007 LATE-BREAKING ABSTRACT: Pseudomonas aeruginosa strain prevalence, adaptation and diversification, during chronic lung infections of UK non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment? Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Impact of Pseudomonas aeruginosa on exacerbation and death in patients with chronic obstructive pulmonary disease. Source: International Congress 2019 – Airway infection in COPD Year: 2019 The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis Source: Eur Respir J 2006; 28: 974-979 Year: 2006 Detection of antibodies against Pseudomonas aeruginosa in the sputum of cystic fibrosis patients: A pilot study Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new basic and clinical physiology research Year: 2012 Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001 Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015